Case report

Synchronous mucinous and non-mucinous lung adenocarcinomas with different epidermal growth mutational status

Rita Linhas a,*, David Tente b, Margarida Dias a, c, Ana Barroso a, c

a Department of Pulmonology, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
b Department of Pathology, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
c Multidisciplinary Unit of Thoracic Tumours, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

Artic le info

Article history:
Received 17 May 2017
Accepted 1 June 2017

Keywords:
Synchronous lung tumors
Immunohistochemistry
EGFR

Abstract

In recent years, the spread of more-sensitive diagnostic methods has resulted in an increase of synchronous multiple primary lung cancer diagnosis. Nevertheless, its occurrence is still rare. Distinction between synchronous lesions from second independent primary tumors is a problem when dealing with multiple lung tumors, particularly if the histological type is the same. We present a case report of a 78-year-old female patient referred to our institution due to pneumonia. A subsequent thoracic computed tomography (CT) was performed showing two suspicious lesions, one in the right upper lobe and the other in the right inferior lobe. The CT-guided transthoracic needle biopsy of both pulmonary lesions revealed two adenocarcinomas, but with a rare combination of distinct morphologic variants, as well as different immunophenotypes and epidermal growth factor receptor (EGFR) gene status. The patient refused surgery and was submitted to stereotactic body radiation therapy (SBRT). She maintained tight follow-up and until now, she has not shown any signs of relapse or metastasis. A multidisciplinary approach with clinical, morphologic and molecular evaluation in multiple lung cancer is important to diagnosis and treatment guidance.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Lung cancer is the most common cause of cancer-related mortality worldwide [1]. Lung adenocarcinoma is the most common form of lung cancer and comprises a group of diseases with heterogeneous clinical and pathological characteristics [2]. Specific histogenetic types of adenocarcinoma, genomic profiles and cancer signaling pathways have been clarified [3–5]. Thus adenocarcinoma has been subject to constant updates in classification and characterization, encompassing different morphological patterns, subtypes and variants, corresponding to different profiles, prognosis and also therapeutic options [6,7].

In recent years, the spread of more-sensitive diagnostic methods has resulted in an increase in the diagnosis of synchronous multiple primary lung cancer (SMPLC) [8]. The assessment of multifocal lung tumors and the distinction of synchronous primary tumors from intrapulmonary metastasis represent an important problem as this decision significantly influences tumor staging and subsequent treatment strategies [9].

A thorough morphologic assessment remains crucial [10,11] and the detection of p53 and EGFR mutations can be useful in the evaluation of multiple primary lung cancers, as the mutational status could help in the differentiation between synchronous tumors and metastasis [12].

This case illustrates a rare occurrence of synchronous lung mucinous and non-mucinous adenocarcinomas with different morphological, immunophenotypical and EGFR mutational status.

2. Case presentation

A 78-year-old female retired nurse, never-smoker (but with passive exposure to the smoke of her sons and husband) with history of arterial hypertension, dyslipidemia and osteo-articular pathology was referred to our institution. The patient had a pneumonia diagnosed 2 months before and she has been treated with amoxicillin/clavulanate 875mg/125mg for 7 days. After 6 weeks, the patient had no symptoms but maintained a
hypotransparency in x-ray.

A thoracic CT was made to clarify the x-ray image and it revealed a lung nodule with a discreet irregular margin that measured 10 mm in the right inferior lobe (RIL) (Fig. 1A) and a 23 mm ground-glass opacity lesion located in the right upper lobe (RUL) (Fig. 1B).

An 8-fluorodeoxyglucose positron emission tomography-CT (PET-CT) scan showed no uptake of the lesions and the brain MRI showed no lesions. An abdominal CT was also performed without identification of additional suspicious lesions. The levels of serum tumor markers such as NSE, Cyfra21.1 and CEA were within normal ranges. The CT-guided transthoracic needle biopsy from the RIL nodule showed a non-mucinous adenocarcinoma with predominant lepidic pattern, type II pneumocyte morphology and phenotype (TTF1 positive). The biopsy from the RUL lesion contained an invasive mucinous adenocarcinoma with predominant lepidic pattern, tall columnar mucinous/goblet cell morphology and mucinous phenotype (TTF1 negative; Napsin A negative; Keratin 7 positive). The mucinous adenocarcinoma from RUL showed negativity for keratin 20 and CDX2 antibodies, favoring a Keratin 7 positive). The mucinous adenocarcinoma of the RIL lesion was evaluated in both tumors. An EGFR exon 19 microdeletion (mutation c.2240_2254del15) was identified in the adenocarcinoma of the RIL lesion, with no EGFR mutation found in the RUL lesion. A RAS mutational analysis was not possible due to insufficient tissue.

A colonoscopy was made and excluded colonic lesions. The different type of cells characterizing each lesion, the distinct immunophenotypes further attested by different EGFR status and the clinical and radiologic data, suggested synchronous adenocarcinoma of the lung. A definitive diagnosis of two synchronous primary lung adenocarcinomas cT1aN0M0 in RIL lesion (stage IA) and cT1bN0M0 in RUL lesion (stage IB) was made. Therapeutic options were discussed with the patient, who refused thoracic surgery. Given the patient’s decision, the multidisciplinary team decided to initiate SBRT. Each lesion was treated using 48 Gy in 4 fractions of 12 Gy, during 8 days in alternate days.

One month after treatment ended CT scan showed discreet dimensional reduction of the RIL lesion, more evident in the 3rd month CT scan. The six months CT scan revealed an enlargement of two lesions what was interpreted as inflammatory lesions induced by radiotherapy. The patient maintained tight follow-up with stable lesions and until now, she has not shown any signs of relapse or adverse effects. Twelve months after the treatment, there are no signs of relapse or metastasis (chest CT, bone scintigraphy, brain magnetic resonance imaging).

3. Discussion

The increasing incidence of multiple primary lung cancers results from the development of higher-resolution chest imaging techniques and closer follow-up of patients with routine chest scans after initial surgical resection. The estimated frequency ranges from 0.2% to 8% as referenced by Gazdar et al. [13]. In another study, among 139 patients with a second malignancy after diagnosis of lung cancer, 78 patients developed a second primary lung cancer, 19 of which were diagnosed synchronously [14]. Among the rare cases of SMPLC, those of the bilateral type comprise 60–70%, while the unilateral type has been comparatively rare [15,16]. With regard to the combination of histological types in SMPLC, the occurrence of squamous cell carcinoma and squamous cell carcinoma has been the most common, followed by squamous cell carcinoma and small cell carcinoma, and squamous cell carcinoma and adenocarcinoma [17]. The combination of two synchronous adenocarcinomas is infrequent and the combination of a mucinous adenocarcinoma and conventional (non-mucinous) adenocarcinoma of the lung is extremely rare.

Before the diagnosis of SMPLC is entertained, the possibility of a metastatic adenocarcinoma to the lung should be excluded. In the case of a lung mucinous adenocarcinoma this discrimination can be troubling because of the morphologic and immunohistochemical similarities its colic and pancreatic counterparts can have. In this instance, endoscopic and radiological data are very important. The assessment of CDX2, keratin 7 and 20 beside TTF1/Napsin A immunomarkers is necessary and molecular evaluation can be a valuable adjunct to this diagnosis [6,7,10,11].

The distinction between multiple synchronous primary lung cancers and intrapulmonary metastasis is often a challenge, being decisive for the therapeutic management and prognosis of these patients. The approach for this distinction has been continuously refined, integrating new criteria and the ever-growing armamentarium of immunohistochemical and molecular resources. The definition of SMPLC came to light in 1924 [18] and Warren and Gates [19] first proposed criteria to the diagnosis in 1938. Martini and Melamed [20] based this distinction on tumors histologic characteristics, besides other features. The emergence of immunohistochemistry and latter molecular biology resulted in a more integrative approach [21,22]. Recently recommendations for resected specimens were published stressing the need for a multidisciplinary approach [23]. In cases of small biopsies the importance of discussing and reviewing all available data is paramount.

The prognosis of SMPLC remains unclear. Whereas the overall
survival rate (OS) of patients diagnosed with SMPLC had been reported to be significantly lower than in patients with single primary lung cancers (SPLC) [24]. Yu et al. reported that there was no significant difference in OS between SPMLC and SPLC [25]. While tumor size is thought to be an important predictor of OS in SMPLC [26], the presence of lymphovascular invasion and the morphologic type of SMPLC do not significantly affect OS according to Yu et al. [27,28]. In another study Shimizu et al. showed that multiple primary lung cancers are potentially curable; the prognosis is usually poor if intrapulmonary metastasis occurred [29]. Surgical treatment, whenever feasible, is considered the modality of choice for the management of patients with second primary lung cancers [30]. Reports of surgical resection of operable synchronous lesions have shown 5-year survival rates of 34–46% [31–33]. However, in this case the patient refused the surgery.

For medically inoperable patients with early stage non-small cell lung cancer SBRT is the first choice and it can be a good option for patients that refuse surgery [34]. Some studies have shown the efficacy and safety of SBRT efficacy and safety of SBRT for MCLC. Matthisien et al. showed in a series of 10 patients excellent local control rates and minimal, clinically acceptable toxicity [35]. In another series of 15 patients the 2-year OS was 68% for patients with metachronous and 28% for patients synchronous MPLC and there was no grade ≥3 toxicities [36]. In a recent study, the local control rate was 99% at 2 years and one year overall survival from the end of SBRT treatment was 85%. There was a 50% chance of developing early toxicity, mostly grade 1 [37].

In light of the present findings, we strongly suggest the need for molecular evaluation of multiple lesions when dealing with synchronous lung adenocarcinomas. For patients with two or more primary cancers a correct diagnosis and staging is critically important because prognosis and treatment vary considerably between multiple primary cancers and metastatic disease. The possibility that one of the tumors is a metastasis has to be excluded, because this would change the stage, and consequently the treatment and the prognosis of the patient. Early diagnosis represents the only possibility to achieve surgical cure and thereby a better prognosis for the patient. To the best of our knowledge, there has been only one other case describing a synchronous mucinous and non-mucinous adenocarcinoma [38].

Conflict of interest

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

References

[1] L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012, CA Cancer J. Clin. 65 (2) (2015 Mar) 87–108.
[2] J. Zugazagoitia, et al., The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects, J. Thorac. Dis. 6 (55) (2014) S526–S536.
[3] Y. Yatabe, T. Kosaka, T. Takahashi, T. Mitsudomi, EGFR mutation is specific for terminal respiratory unit type adenocarcinoma, Am. J. Surg. Pathol. 29 (5) (2005 May).
[4] Y. Yatabe, EGFR mutations and the terminal respiratory unit, Cancer Metastasis Rev. 29 (2010) 23–36.
[5] Cancer Genome Atlas Research Network, Comprehensive molecular profiling of lung adenocarcinoma, Nature 511 (7511) (2014 Jul) 543–550.
[6] W.D. Travis, E. Brambilla, M. Noguchi, A.G. Nicholson, K.R. Geisinger, Y. Yatabe, International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma, J. Thorac. Oncol. 6 (2) (2011 Feb) 244–285.
[7] WHO, in: Lyon (Ed.), WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, fourth ed., International Agency for Research on Cancer (IARC), France, 2015.
[8] M. Riquet, A. Cazes, K. Pfeuty, et al., Multiple lung cancers prognosis: what about histology? Ann. Thorac. Surg. 86 (3) (2008) 921–926.
[9] A. Warth, S. Machar-Goepperinger, T. Muley, et al., Clonality of multifocal non-small cell lung cancer: implications for staging and therapy, Eur. Respir. J. 39 (2012) 1437–1442, 15:375-80.
[10] G. Rossi, A. Cavaza, L. Righi, G. Sartori, A. Bisagni, L. Longo, G. Pelosi, M. Papotti, Napsin-A, TTF-1, EGFR, and ALK status determination in lung primary and metastatic mucin-producing adenocarcinomas, Int. J. Surg. Pathol. 22 (5) (2014 Aug) 401–407.
[11] A.M. Krasinskas, S.J. Chiosea, T. Pal, S. Dacic, KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas, Mod. Pathol. 22 (7) (2009 Jul) 910–916.
[12] Y.L. Hang, C.T. Wu, S.C. Lin, C.F. Hsiao, Y.S. Jou, Y.C. Lee, Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers, Clin. Cancer Res. 13 (1) (2007) 52–58.
[13] A.F. Gazdar, J.D. Minna, Multifocal lung cancers-clonality vs field cancerization and does it matter? J. Natl. Cancer Inst. 101 (2009) 541–543.
[14] N. Reinmuth, Characteristics and outcome of patients with second primary lung cancer, Eur. Respir. J. 42 (2013) 1668–1676.
[15] T. Morita, Incidence, contents and change of autopsied multiple primary cancers of the lung based on the annual of the autopsy cases in Japan between 1958 and 1992, Haigan 37 (1997) 283–294.
[16] S. Matsuge, Y. Hosokawa, K. Sato, et al., Surgical treatment for bilateral multiple lung cancers, Kyobu Geka 53 (2000) 89–95.
Y. Kobashi, M. Fukuda, K. Yoshida, et al., Synchronous presentation of early stage small cell carcinoma and adenocarcinoma in the same lung lobe, Intern Med. 45 (2006) 287–289.

H. Beyreuther, Multiplizitat von Carcinomen Bei Einem Fall von sog: “Schneeburger” Lungenkrebs Mit Tuberkulose, Virchows Arch. Pathol. Anat. Physiol. 250 (1924) 230–243.

S. Warren, G. Gates, Multiple primary malignant tumors: a survey of the literature and a statistical study, Am. J. Cancer 16 (1932) 1358–1414.

N. Martini, M.R. Melamed, Multiple primary lung cancers, J. Thorac. Cardiovasc. Surg. 70 (1975) 606–611.

X. Xue, Y. Liu, L. Pan, Y. Wang, K. Wang, M. Zhang, P. Wang, J. Wang, Diagnosis of multiple primary lung cancer: a systematic review, J. Int. Med. Res. 41 (6) (2013 Dec) 1779–1787.

N. Girard, C. Deshpande, C. Lau, D. Finley, V. Rusch, W. Pao, W.D. Travis, Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases, Am. J. Surg. Pathol. 33 (12) (2009 Dec) 1752–1764.

D.C. Detterbeck, W.A. Franklin, A.G. Nicholson, N. Girard, D.A. Aeneberg, W.D. Travis, P.J. Mazzone, E.M. Marom, J.S. Donington, L.T. Tanoue, V.W. Rusch, H. Asamura, R. Rami-Porta, IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup, The IASLC lung cancer staging project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer, J. Thorac. Oncol. 11 (5) (2016 May) 651–665.

M.K. Ferguson, T.R. DeMeester, J. DesLauriers, et al., Diagnosis and management of synchronous lung cancers, J. Thorac. Cardiovasc. Surg. 89 (1985) 378–385.

Y.C. Yu, P.K. Hsu, Y.C. Yeh, et al., Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers? Ann. Thorac. Surg. 96 (2013) 1966–1974.

T. Antakli, R.F. Schaefer, J.E. Rutherford, R.C. Read, Second primary lung cancer, Ann. Thorac. Surg. 59 (4) (1995) 863–866.

H. Rostad, T.E. Strand, A. Naalsund, J. Norstein, Resected synchronous primary malignant lung tumors: a population-based study, Ann. Thorac. Surg. 85 (2008) 204–209.

L. Volotolino, C. Ricpetta, L. Luzzi, et al., Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in nodenegative subgroup, Eur. J. Cardiothorac. Surg. 37 (2010) 1198–1204.

S. Shimizu, Y. Yatabe, T. Koshikawa, et al., High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis, Clin. Cancer Res. 6 (2000) 3994–3999.

A. Loukeri Angeliki, Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis, Clin. Lung Cancer 16 (1) (2015) 15–23.

D. Trousse, F. Barlesi, A. Loundou, et al., Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management, J. Thorac. Cardiovasc. Surg. 133 (2007) 1193–1200.

E.J. Jung, J.H. Lee, K. Jeon, et al., Treatment outcomes for patients with synchronous multiple primary non-small cell lung cancer, Lung Cancer 73 (2011) 237–242.

P. De Leyn, J. Moons, J. Vansteenkiste, et al., Survival after resection of synchronous bilateral lung cancer, Eur. J. Cardiothorac. Surg. 34 (2008) 1215–1222.

R.O. Mirimanoff, Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung? Clin. Oncol. 4 (4) (2015) 42.

C. Matthiesen, J.S. Thompson, T. Herman, S. Ahmad, T. Herman, Use of stereotactic body radiation therapy for medically inoperable multiple primary lung cancer, J. Med. Imaging Radiat. Oncol. 56 (2012) 561–566.

I.M. Creach, J.D. Bradley, P. Mahasittiwat, C.G. Robinson, Stereotactic body radiation therapy in the treatment of multiple primary lung cancers, Radiother. Oncol. 104 (2012) 19–22.

D. Owen, et al., Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules, Radiat. Oncol. 10 (2015) 43.

H.J. Yoon, H.Y. Lee, J. Han, Y.L. Choi, Synchronous triple primary lung cancers: a case report, Korean J. Radiol. 15 (5) (2014) 646–650.